Literature DB >> 21311969

Unfavourable pattern of metastases in M0 breast cancer patients during 1978-2008: a population-based analysis of the Munich Cancer Registry.

Corina J G van den Hurk1, Renate Eckel, Lonneke V van de Poll-Franse, Jan Willem W Coebergh, Johan W R Nortier, Dieter Hölzel, Wim P M Breed, Jutta Engel.   

Abstract

Little is known about time trends in metastases in the patients treated in routine health care facilities without metastases at diagnosis (M0) and about survival after these metastases. Data on 33,771 M0 patients with primary breast cancer diagnosed between 1978 and 2003 were obtained from the Munich Cancer Registry. Survival analyses were restricted to the patients with metastases within 5 years of the initial diagnosis. The incident number of the patients approximately doubled each period and 5-year overall survival increased from 77% in the first to 82% percent in the last period. 5490 (16%) M0 patients developed metastases within 5 years after the initial diagnosis. The hazard of developing metastases was lowest in the most recent period compared to the first period (HR = 0.50, P < 0.001). The hazard of dying after metastases was equal for patients diagnosed between 1978-1984 and 1995-2003 (HR 1.08, P = 0.3). The percentage of the patients that developed bone metastases decreased each time period, but the percentage primary liver and CNS metastases increased. Exclusion of site of metastases in the multivariate analysis led to a 20% (P = 0.02) higher hazard of dying following metastases in the last versus the first period. In the period 1978-2008, unfavourable changes in the pattern of metastases were exhibited and no improvement was observed in survival of the patients after occurrence of metastases. An explanation might be the increased use of adjuvant systemic treatment, which has less effect on the highly lethal liver and CNS metastases than on bone metastases. The increased use also appeared to contribute to the overall prevention of metastases in breast cancer and therefore to improve overall survival.

Entities:  

Mesh:

Year:  2011        PMID: 21311969     DOI: 10.1007/s10549-011-1372-y

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  15 in total

1.  Cutaneous metastasis of a breast cancer diagnosed 13 years before.

Authors:  Maraya de Jesus Semblano Bittencourt; Alessandra Haber Carvalho; Bianca Angelina Macêdo do Nascimento; Lívia Karlla Marinho Freitas; Amanda Magno de Parijós
Journal:  An Bras Dermatol       Date:  2015 May-Jun       Impact factor: 1.896

2.  Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry.

Authors:  Dieter Hölzel; Renate Eckel; Ingo Bauerfeind; Bernd Baier; Thomas Beck; Michael Braun; Johannes Ettl; Ulrich Hamann; Marion Kiechle; Sven Mahner; Christian Schindlbeck; Johann de Waal; Nadia Harbeck; Jutta Engel
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-20       Impact factor: 4.553

3.  Survival of de novo stage IV breast cancer patients over three decades.

Authors:  Dieter Hölzel; Renate Eckel; Ingo Bauerfeind; Bernd Baier; Thomas Beck; Michael Braun; Johannes Ettl; Ulrich Hamann; Nadia Harbeck; Marion Kiechle; Sven Mahner; Christian Schindlbeck; Johann de Waal; Jutta Engel
Journal:  J Cancer Res Clin Oncol       Date:  2016-11-16       Impact factor: 4.553

4.  MiR-124 inhibits cell proliferation in breast cancer through downregulation of CDK4.

Authors:  Tongbao Feng; Dongqin Xu; Chao Tu; Wenjing Li; Yongling Ning; Jun Ding; Shizhong Wang; Liudi Yuan; Ning Xu; Keqing Qian; Yong Wang; Chunjian Qi
Journal:  Tumour Biol       Date:  2015-03-03

5.  Sensor-controlled scalp cooling to prevent chemotherapy-induced alopecia in female cancer patients.

Authors:  M K Fehr; J Welter; W Sell; R Jung; R Felberbaum
Journal:  Curr Oncol       Date:  2016-12-21       Impact factor: 3.677

6.  Antidepressant use and risk of central nervous system metastasis.

Authors:  Megan M Herr; Nimish A Mohile; Edwin van Wijngaarden; Edward B Brown; David Q Rich
Journal:  J Neurooncol       Date:  2016-06-11       Impact factor: 4.130

7.  Can We Use Survival Data from Cancer Registries to Learn about Disease Recurrence? The Case of Breast Cancer.

Authors:  Angela B Mariotto; Zhaohui Zou; Fanni Zhang; Nadia Howlader; Allison W Kurian; Ruth Etzioni
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-10-18       Impact factor: 4.254

8.  Monitoring the progression of metastatic breast cancer on nanoporous silica chips.

Authors:  Jia Fan; Xiaoyong Deng; James W Gallagher; Haiyu Huang; Yi Huang; Jianguo Wen; Mauro Ferrari; Haifa Shen; Ye Hu
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2012-05-28       Impact factor: 4.226

9.  Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States.

Authors:  Natalia Kunst; Fernando Alarid-Escudero; Eline Aas; Veerle M H Coupé; Deborah Schrag; Karen M Kuntz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-09-30       Impact factor: 4.254

10.  Hospital visits among women with skeletal-related events secondary to breast cancer and bone metastases: a nationwide population-based cohort study in Denmark.

Authors:  Marie Louise Svendsen; Henrik Gammelager; Claus Sværke; Mellissa Yong; Victoria M Chia; Christian F Christiansen; Jon P Fryzek
Journal:  Clin Epidemiol       Date:  2013-03-26       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.